This wave of Hatch-Waxman cases comes as patent disputes involving GLP-1 receptor agonists, especially Novo Nordisk's Ozempic ...

Novo Nordisk CEO defended the company's decision to sue rival Eli Lilly over its weight-loss drug advertising.

Novo Nordisk sued Eli Lilly in New Jersey, alleging deceptive ads comparing high-dose Zepbound to lower doses of Wegovy.

Two of the world's biggest pharmaceutical companies are headed to court after Novo Nordisk, the maker of Ozempic and a pioneer in diabetes and obesity treatments, sued rival Eli Lilly on Tuesday, ...

The clash between pharma titans Novo Nordisk and Eli Lilly just escalated from the pharmacy counter to the courtroom. Novo Nordisk Inc. filed a lawsuit in the U.S. District Court for the District of ...

Novo alleges Lilly compared the highest approved doses of its medicines with lower doses of Novo’s Wegovy and Ozempic while omitting newer, higher-dose versions that Novo says deliver greater weight ...

This week, GLP-1 heavyweight Novo Nordisk (NVO +0.56%) sued the leading GLP-1 drugmaker, Eli Lilly (LLY +4.86%), claiming its television ads are deceptive because they state that Lilly's Zepbound is ...

Novo Nordisk claims Eli Lilly aired misleading ads comparing the pharma companies' respective weight-loss drugs, Wegovy and Zepbound.

Novo asked the court to permanently stop Lilly from running the "deceptive" ads and require the drugmaker to issue corrective advertising.